bricanyl turbuhaler innöndunarduft 0,25 mg/úðaskammt
astrazeneca a/s - terbutalinum súlfat - innöndunarduft - 0,25 mg/úðaskammt
aburic filmuhúðuð tafla 80 mg
williams & halls ehf. - febuxostatum inn - filmuhúðuð tafla - 80 mg
bufomix easyhaler innöndunarduft 160 míkróg/4,5 míkróg/skammt
orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 160 míkróg/4,5 míkróg/skammt
bufomix easyhaler innöndunarduft 320 míkróg/9 míkróg/skammt
orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320 míkróg/9 míkróg/skammt
depo-medrol stungulyf, dreifa 40 mg/ml
pfizer aps - methylprednisolonum acetat - stungulyf, dreifa - 40 mg/ml
febuxostat medical valley filmuhúðuð tafla 80 mg
medical valley invest ab - febuxostatum inn - filmuhúðuð tafla - 80 mg
persantin húðuð tafla 100 mg
glenwood gmbh pharmazeutische erzeugnisse - dipyridamolum inn - húðuð tafla - 100 mg
solu-cortef stungulyfsstofn og leysir, lausn 100 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 100 mg
solu-cortef stungulyfsstofn og leysir, lausn 250 mg
pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg
bropair spiromax
teva b.v. - salmeterol xinafoate, flútikasón nef - astma - lyf til veikindi öndunarvegi sjúkdómum, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.